Kyowa Kirin Co., Ltd. (4151.T) Stock
Kyowa Kirin Co., Ltd.

Company profile
Kyowa Kirin reported revenue of 496.83 billion JPY for fiscal year 2025, up 0.3% from fiscal year 2024, and net income of 67.04 billion JPY. That is a net profit margin of 13.5% for fiscal year 2025. United States was its largest region in fiscal year 2025, with 48% of revenue. Our analysis of its filings shows revenue growing from 442.23 billion JPY in fiscal year 2023 to 496.83 billion JPY in fiscal year 2025, 6.0% a year on average. Kyowa Kirin reports about 5,161 full-time employees.
What stands out
- It spent 101.18 billion JPY on research and development in fiscal year 2025, 20.4% of its revenue.
- Revenue in fiscal year 2025 was the highest of the last 5 fiscal years.
Figures from company filings; latest fiscal year ended December 31, 2025.
About Kyowa Kirin Co., Ltd.
Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, and marketing of pharmaceuticals in Japan, the Americas, Europe, Asia, and internationally. The company offers Ziftomenib, an oral menin inhibitor for the treatment of adult relapsed or refractory and acute myeloid leukemia with a nucelophosmin1 mutation; and Lumicef for the treatment of palmoplantar pustulosis. It also develops KHK4083/AMG 451 rocatinlimab, which is in Phase III clinical trial for the treatment of moderate to severe atopic dermatitis and prurigo nodularis; KK8398 infigratinib, which is in Phase III clinical trial for the treatment of achondroplasia; OTL-203, which is in Phase III clinical trial for the treatment of hurler syndrome; KHK4951 tivozanib, which is in Phase II clinical trial for the treatment of diabetic macular edema and neovascular age-related macular degeneration; and OTL-201, which is in Phase II clinical trial for the treatment of sanfilippo syndrome type A. In addition, the company is involved in the development of KK2260 and KK2269, which are both in Phase I clinical trials for the treatment of advanced or metastatic solid tumors; KK2845, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; KK3910, which is in Phase I clinical trial for the treatment of essential hypertension; KK4277, which is in Phase I clinical trial for the treatment of systemic/cutaneous lupus erythematosus; and KK8123, which is in Phase I clinical trial for the treatment of X-linked hypophosphatemia. It has a partnership with La Jolla Institute for Immunology for research in disease areas; AstraZeneca for severe asthma treatment; and AMGEN for therapeutic drugs development. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in July 2019. Kyowa Kirin Co., Ltd. was incorporated in 1949 and is headquartered in Chiyoda, Japan. The company operates as a subsidiary of Kirin Holdings Company, Limited.
Largest shareholders
- Kirin Holdings Company, Limited54.95%
- Kyowa Kirin Co., Ltd.0.41%
- Simplex Asset Management Co., Ltd.0.26%
- FIL Investments (Japan) Ltd.0.13%
- Kewpie Pension Fund0.09%
Share of the company, as of September 25, 2026
Leadership
- Abdul Hafeez Mullick Ph.D. — President, CEO & Representative Director, 58
- Koji Igarashi — Chief Financial Officer
- Shoko Itagaki — Managing Executive Officer, Chief People Officer & Global Human Resources Head
- Takeyoshi Yamashita Ph.D. — Executive VP, Chief Scientific Officer & Director, 64
- Yasuo Fujii M.B.A. — Chief Business Officer, VP & Managing Executive Officer, 61
How much revenue does Kyowa Kirin make?
Kyowa Kirin reported 496.83 billion JPY in revenue for fiscal year 2025, up 0.3% from 495.56 billion JPY in fiscal year 2024.
Where does Kyowa Kirin make most of its revenue?
United States: 48% of revenue by region in fiscal year 2025, followed by Japan (26%).
What companies are similar to Kyowa Kirin?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Daiichi Sankyo Company, Limited (4568.T), Astellas Pharma Inc. (4503.T), Eisai Co., Ltd. (4523.T), Ono Pharmaceutical Co., Ltd. (4528.T).
How has Kyowa Kirin's revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2021, 352.25 billion JPY; FY2022, 398.37 billion JPY; FY2023, 442.23 billion JPY; FY2024, 495.56 billion JPY; FY2025, 496.83 billion JPY.
Company Information
Contact & Links
Data as of .
How to cite: DataPorium, “Kyowa Kirin Co., Ltd. (4151.T)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/4151.T